A single domain shark antibody targeting the transferrin receptor 1 delivers a TrkB agonist antibody across the blood brain barrier to provide full neuroprotection in a mouse model of Parkinson's Disease
Emily ClarkeiD, Liz Sinclair, Edward J. R. FletcheriD, Alicja Krawczun-RygmaczewskaiD, Susan DutyiD, Paweł StockiiD, Julia Lynn Rutkowski, Patrick DohertyiD, Frank S. Walsh
Abstract
Single domain shark antibodies that bind to the transferrin receptor 1 (TfR1) on brain endothelial cells can be used to shuttle antibodies and other cargos across the blood brain barrier (BBB). We have fused one of these (TXB4) to differing regions of TrkB and TrkC neurotrophin receptor agonist antibodies (AAb) and determined the effect on agonist activity, brain accumulation and engagement with neurons in the mouse brain following systemic administration. The TXB4-TrkB and TXB4-TrkC fusion proteins retain agonist activity at their respective neurotrophin receptors and in contrast to their parental AAb they rapidly accumulate in the brain reaching nM levels following a single IV injection. Following SC administration, the most active TrkB fusion protein, TXB4-TrkB1, associates with and activates ERK1/2 signalling in TrkB positive cells in the cortex and tyrosine hydroxylase (TH) positive dopaminergic neurons in the substantia nigra pars compacta (SNc). When tested in the 6-hydroxydopamine (6-OHDA) mouse model of Parkinsons disease (PD) TXB4-TrkB1, but not the parental TrkB AAb or a TXB4-TrkC1 fusion protein, completely prevented the 6-OHDA induced death of TH positive neurons in the SNc. In conclusion, the fusion of the TXB4 TfR1 binding module allows a TrkB AAb to reach neuroprotective concentrations in the brain parenchyma following systemic administration.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 3
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Blood-brain barrier transport using a high-affinity, brain-selective VNAR (Variable Domain of New Antigen Receptor) antibody targeting transferrin receptor 1
Paweł Stocki, Jarosław Szary, … Julia Lynn Rutkowski·bioRxiv·Jul 20, 2020
- Molecular mechanism of action of a blood brain barrier shuttle antibody
Sulin Liu, Ollie King, … Paul S. Miller·bioRxiv·Jul 5, 2026
- GDNF receptor agonist supports dopamine neurons in vitro and protects their function in animal model of Parkinson's disease.
Arun Kumar Mahato, Juho‐Matti Renko, … Märt Saarma·bioRxiv·Feb 4, 2019
- Neuroprotective activity of sub-anesthetic ketamine in a preclinical model of Parkinson's disease is not blocked by antagonizing brain-derived neurotrophic factor signaling
Carolyn J. Stopera, Mitchell J. Bartlett, … Torsten Falk·bioRxiv·Oct 29, 2026
- Chronic activation of dopaminergic neurons via bioluminescence-optogenetics provides neuroprotection in a rodent model of Parkinson's disease
Fu Hung Shiu, Henry M. Skelton, … Robert E. Gross·bioRxiv·Oct 17, 2022
- Transferrin receptor-binding blood-brain barrier shuttle enhances brain delivery and efficacy of a therapeutic anti-Abeta antibody
Marta Ramos Vega, Henrik H. Hansen, … Jacob Hecksher‐Sørensen·bioRxiv·Feb 14, 2025